SEDI Insider filing browser
Filter by Company
×
Filter by $CAD Amount
×
Filter by Filing Type
Filter by Insider
×
 
Date Issuer Insider Transaction Amount New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
Filed 2019-12-13 08:45
Tx date 2019-12-12
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$700.00
+1,000 vol
$0.70 each
3,909,207
Filed 2019-12-13 08:45
Tx date 2019-12-11
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$27.60
+40 vol
$0.69 each
3,908,207
Filed 2019-12-13 08:44
Tx date 2019-12-10
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,597
+5,202 vol
$0.69 each
3,908,167
Filed 2019-12-09 17:50
Tx date 2019-12-09
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,150
+4,500 vol
$0.70 each
3,902,965
Filed 2019-12-09 17:46
Tx date 2019-12-09
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,150
+4,500 vol
$0.70 each
Filed 2019-12-09 17:45
Tx date 2019-12-06
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$28.00
+40 vol
$0.70 each
3,898,465
Filed 2019-12-09 17:44
Tx date 2019-12-05
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,611
+5,160 vol
$0.70 each
3,898,425
Filed 2019-12-09 17:40
Tx date 2019-12-09
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$3,150
+4,500 vol
$0.70 each
Filed 2019-12-09 17:39
Tx date 2019-12-06
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$28.00
+40 vol
$0.70 each
Filed 2019-12-09 17:39
Tx date 2019-12-05
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$3,611
+5,160 vol
$0.70 each
Filed 2019-11-26 18:19
Tx date 2019-11-22
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$67,033
+89,845 vol
$0.75 each
3,893,265
Filed 2019-10-16 19:54
Tx date 2019-10-11
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$64,900
+100,000 vol
$0.65 each
3,803,420
Filed 2019-10-16 19:52
Tx date 2019-09-23
$NVLN
Novelion Therapeutics Inc.
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
3,703,420
Filed 2019-09-27 16:24
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,282.88
-1,688 vol
$0.76 each
15,391
Filed 2019-09-27 16:18
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$4,357
+5,733 vol
$0.76 each
17,079
Filed 2019-09-27 16:18
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-4,357.08
-5,733 vol
$0.76 each
996
Filed 2019-09-27 16:16
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$10,133
+13,333 vol
$0.76 each
14,111
Filed 2019-09-27 16:16
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-10,133.08
-13,333 vol
$0.76 each
0
Filed 2019-09-27 16:15
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$10,133
+13,333 vol
$0.76 each
Filed 2019-09-27 16:14
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-10,133.08
-13,333 vol
$0.76 each
Filed 2019-09-27 16:14
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-2,983.76
-3,926 vol
$0.76 each
778
Filed 2019-09-27 16:13
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$10,133
+13,333 vol
$0.76 each
Filed 2019-09-27 16:13
Tx date 2019-09-24
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-10,133.08
-13,333 vol
$0.76 each
Filed 2019-05-14 11:35
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-93.94
-77 vol
$1.22 each
570
Filed 2019-05-14 11:35
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$333.06
+273 vol
$1.22 each
647
Filed 2019-05-14 11:34
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-333.06
-273 vol
$1.22 each
47,980
Filed 2019-05-14 11:30
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-189.10
-155 vol
$1.22 each
1,162
Filed 2019-05-14 11:30
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$666.12
+546 vol
$1.22 each
1,317
Filed 2019-05-14 11:28
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-666.12
-546 vol
$1.22 each
20,560
Filed 2019-05-14 11:18
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-258.64
-212 vol
$1.22 each
3,683
Filed 2019-05-14 11:18
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$880.84
+722 vol
$1.22 each
3,895
Filed 2019-05-14 11:16
Tx date 2019-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-880.84
-722 vol
$1.22 each
47,982
Filed 2019-03-19
Tx date 2019-03-15
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,254.96
-996 vol
$1.26 each
11,346
Filed 2019-03-19
Tx date 2019-03-15
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$2,357
+1,871 vol
$1.26 each
12,342
Filed 2019-03-19
Tx date 2019-03-15
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-2,357.46
-1,871 vol
$1.26 each
6,729
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-81,446.908
-83,245 vol
$0.98 each
1,863,709
Filed 2018-12-27
Tx date 2018-12-24
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-392.00
-400 vol
$0.98 each
1,948,154
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-81,446.908
-83,245 vol
$0.98 each
1,863,709
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,119
-1,200 vol
$0.93 each
1,946,954
Filed 2018-12-27
Tx date 2018-12-24
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-392.00
-400 vol
$0.98 each
1,948,154
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-1,119
-1,200 vol
$0.93 each
1,946,954
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-81,446.908
-83,245 vol
$0.98 each
1,863,709
Filed 2018-12-27
Tx date 2018-12-24
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-392.00
-400 vol
$0.98 each
1,948,154
Filed 2018-12-27
Tx date 2018-12-26
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
10 - Acquisition or disposition in the public market
$-1,119
-1,200 vol
$0.93 each
1,946,954
Filed 2018-12-10
Tx date 2018-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-14,400
-11,250 vol
$1.28 each
8,600
Filed 2018-12-10
Tx date 2018-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$14,400
+11,250 vol
$1.28 each
13,784
Filed 2018-12-10
Tx date 2018-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-4,240.64
-3,313 vol
$1.28 each
10,471
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$6,132
+6,667 vol
$0.92 each
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$1,805
+1,963 vol
$0.92 each
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$6,132
+6,667 vol
$0.92 each
6,667
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$1,805
+1,963 vol
$0.92 each
Filed 2018-11-28
Tx date 2017-12-04
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$6,132
+6,667 vol
$0.92 each
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-6,132.9733
-6,667 vol
$0.92 each
13,333
Filed 2018-11-28
Tx date 2018-11-27
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,805.7637
-1,963 vol
$0.92 each
4,704
Filed 2018-11-05
Tx date 2018-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-386.12
-98 vol
$3.94 each
Filed 2018-11-05
Tx date 2018-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-386.12
-98 vol
$3.94 each
Filed 2018-11-05
Tx date 2018-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-622.50
-150 vol
$4.15 each
Filed 2018-11-05
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-1,371.72
-322 vol
$4.26 each
Filed 2018-11-05
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$28,840
+32,149 vol
$0.90 each
Filed 2018-11-05
Tx date 2018-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-622.50
-150 vol
$4.15 each
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-28,840.8679
-32,149 vol
$0.90 each
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$97,933
+109,167 vol
$0.90 each
109,167
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-97,933.7157
-109,167 vol
$0.90 each
33,333
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-28,840.8679
-32,149 vol
$0.90 each
Filed 2018-11-05
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-1,371.72
-322 vol
$4.26 each
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-28,840.8679
-32,149 vol
$0.90 each
77,018
Filed 2018-11-05
Tx date 2018-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$28,840
+32,149 vol
$0.90 each
Filed 2018-09-18
Tx date 2018-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights
$-1,323.84
-336 vol
$3.94 each
48,704
Filed 2018-09-18
Tx date 2018-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights
$1,323
+336 vol
$3.94 each
3,271
Filed 2018-09-18
Tx date 2018-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-386.12
-98 vol
$3.94 each
3,173
Filed 2018-08-27
Tx date 2018-08-22
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+50,000 vol
136,665
Filed 2018-08-14
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$33,300
+10,000 vol
$3.33 each
19,600
Filed 2018-08-14
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-14
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-14
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2018-08-14
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$-3.33
-1 vol
$3.33 each
0
Filed 2018-08-14
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$3.33
+1 vol
$3.33 each
1
Filed 2018-08-14
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$3.33
+1 vol
$3.33 each
2
Filed 2018-08-14
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$3.33
+1 vol
$3.33 each
2
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
29,600
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Stern, Donald
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
19,600
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
29,600
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Orloff, John
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
185,620
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
DiPaolo, Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
19,600
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+50,000 vol
59,600
Filed 2018-08-13
Tx date 2018-08-09
$NVLN
Novelion Therapeutics Inc.
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+10,000 vol
19,600
Filed 2018-07-16
Tx date 2018-03-13
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Global Growth & Income Portfolio (Control or Direction)
Convertible Notes
11 - Acquisition or disposition carried out privately
$
+$750,000 vol
$77.00 each
$35,916,800
Filed 2018-07-16
Tx date 2017-11-07
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Global Growth & Income Portfolio (Control or Direction)
Convertible Notes
00 - Opening Balance-Initial SEDI Report
$35,166,800
Filed 2018-07-16
Tx date 2017-11-07
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Convertible Notes
00 - Opening Balance-Initial SEDI Report
$4,000,000
Filed 2018-07-16
Tx date 2017-11-07
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Convertible Notes
00 - Opening Balance-Initial SEDI Report
$12,475,200
Filed 2018-07-16
Tx date 2018-01-02
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$5,811
+1,833 vol
$3.17 each
1,350,323
Filed 2018-07-16
Tx date 2017-12-06
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$527,544
+150,727 vol
$3.50 each
1,348,490
Filed 2018-07-16
Tx date 2017-12-05
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$50,561
+14,446 vol
$3.50 each
1,197,763
Filed 2018-07-16
Tx date 2017-12-05
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$386,387
+104,840 vol
$3.69 each
1,183,317
Filed 2018-07-16
Tx date 2017-12-01
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,334
+883 vol
$3.78 each
1,078,477
Filed 2018-07-16
Tx date 2017-12-01
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$16,355
+4,389 vol
$3.73 each
1,077,594
Filed 2018-07-16
Tx date 2017-11-15
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$33,733
+7,681 vol
$4.39 each
1,073,205
Filed 2018-07-16
Tx date 2017-11-14
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$36,599
+8,328 vol
$4.39 each
1,065,524
Filed 2018-07-16
Tx date 2017-11-13
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$784.83
+181 vol
$4.34 each
1,057,196
Filed 2018-07-16
Tx date 2017-11-10
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$17,094
+3,949 vol
$4.33 each
1,057,015
Filed 2018-07-16
Tx date 2017-11-09
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$3,091
+719 vol
$4.30 each
1,053,066
Filed 2018-07-16
Tx date 2017-11-07
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
1,052,347
Filed 2018-07-16
Tx date 2018-01-02
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$4,175
+1,317 vol
$3.17 each
844,740
Filed 2018-07-16
Tx date 2017-12-06
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$337,939
+96,554 vol
$3.50 each
843,423
Filed 2018-07-16
Tx date 2017-12-05
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$247,518
+67,160 vol
$3.69 each
746,869
Filed 2018-07-16
Tx date 2017-12-05
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$32,389
+9,254 vol
$3.50 each
679,709
Filed 2018-07-16
Tx date 2017-12-01
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$10,474
+2,811 vol
$3.73 each
670,455
Filed 2018-07-16
Tx date 2017-12-01
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$2,137
+566 vol
$3.78 each
667,644
Filed 2018-07-16
Tx date 2017-11-15
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$18,375
+4,184 vol
$4.39 each
667,078
Filed 2018-07-16
Tx date 2017-11-14
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$19,943
+4,538 vol
$4.39 each
662,894
Filed 2018-07-16
Tx date 2017-11-13
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$429.27
+99 vol
$4.34 each
658,356
Filed 2018-07-16
Tx date 2017-11-10
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$9,311
+2,151 vol
$4.33 each
658,257
Filed 2018-07-16
Tx date 2017-11-09
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
10 - Acquisition or disposition in the public market
$1,681
+391 vol
$4.30 each
656,106
Filed 2018-07-16
Tx date 2017-11-07
$NVLN
Novelion Therapeutics Inc.
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
655,715
Filed 2018-05-17
Tx date 2018-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately

-150 vol
2,935
Filed 2018-05-17
Tx date 2018-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-512 vol
49,040
Filed 2018-05-17
Tx date 2018-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+512 vol
3,085
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-547 vol
21,106
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-685.86
-161 vol
$4.26 each
771
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+547 vol
932
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-748 vol
49,552
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-349 vol
50,300
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-937.20
-220 vol
$4.26 each
2,573
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+748 vol
2,793
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-434.52
-102 vol
$4.26 each
2,045
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+349 vol
2,147
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-340.80
-80 vol
$4.26 each
374
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+273 vol
454
Filed 2018-05-11
Tx date 2018-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-273 vol
48,253
Filed 2018-04-03
Tx date 2018-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-177 vol
50,649
Filed 2018-04-03
Tx date 2018-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-182.00
-52 vol
$3.50 each
1,798
Filed 2018-04-03
Tx date 2018-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$182.00
+52 vol
$3.50 each
Filed 2018-04-03
Tx date 2018-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$182.00
+52 vol
$3.50 each
Filed 2018-04-03
Tx date 2018-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+177 vol
1,850
Filed 2018-03-26
Tx date 2018-03-15
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+8,600 vol
19,850
Filed 2018-03-26
Tx date 2018-03-15
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+40,000 vol
86,665
Filed 2018-03-16
Tx date 2018-03-15
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants
53 - Grant of warrants

+909,296 vol
909,296
Filed 2018-03-16
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-16
Tx date 2018-03-15
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants
53 - Grant of warrants

+909,296 vol
909,296
Filed 2018-03-16
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2018-03-16
Tx date 2018-03-15
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants
53 - Grant of warrants

+909,296 vol
909,296
Filed 2018-03-16
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants
00 - Opening Balance-Initial SEDI Report
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+45,000 vol
245,000
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+25,000 vol
66,740
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+45,000 vol
217,400
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+25,000 vol
122,400
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+25,000 vol
Filed 2018-02-14
Tx date 2018-02-12
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+25,000 vol
Filed 2017-12-11
Tx date 2017-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
57 - Exercise of rights

-3,750 vol
11,250
Filed 2017-12-11
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-60,000 vol
15,000
Filed 2017-12-11
Tx date 2017-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-4,049.28
-1,216 vol
$3.33 each
2,534
Filed 2017-12-11
Tx date 2017-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
57 - Exercise of rights

+3,750 vol
3,750
Filed 2017-12-11
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-07
Tx date 2017-12-04
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+20,000 vol
20,000
Filed 2017-12-07
Tx date 2017-12-04
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2017-12-07
Tx date 2017-12-04
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+100,000 vol
100,000
Filed 2017-12-07
Tx date 2017-12-04
$NVLN
Novelion Therapeutics Inc.
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-30
Tx date 2017-11-27
$NVLN
Novelion Therapeutics Inc.
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
50,000
Filed 2017-11-30
Tx date 2017-11-27
$NVLN
Novelion Therapeutics Inc.
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
200,000
Filed 2017-11-03
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+92,500 vol
142,500
Filed 2017-11-03
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+50,000 vol
50,000
Filed 2017-11-03
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2017-11-03
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+135,000 vol
135,000
Filed 2017-11-03
Tx date 2017-11-01
$NVLN
Novelion Therapeutics Inc.
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-10-10
Tx date 2017-10-06
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+75,000 vol
172,400
Filed 2017-10-05
Tx date 2017-10-02
$NVLN
Novelion Therapeutics Inc.
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
9,600
Filed 2017-10-05
Tx date 2017-10-01
$NVLN
Novelion Therapeutics Inc.
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-09-19
Tx date 2017-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-337 vol
50,826
Filed 2017-09-19
Tx date 2017-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-771.72
-109 vol
$7.08 each
1,673
Filed 2017-09-19
Tx date 2017-09-17
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+337 vol
1,782
Filed 2017-08-02
Tx date 2017-08-02
$NVLN
Novelion Therapeutics Inc.
DiPaolo, Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
9,600
Filed 2017-07-05
Tx date 2017-07-03
$NVLN
Novelion Therapeutics Inc.
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
175,620
Filed 2017-06-14
Tx date 2017-06-12
$NVLN
Novelion Therapeutics Inc.
Stern, Donald
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$22,750
+2,500 vol
$9.10 each
2,500
Filed 2017-06-14
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Stern, Donald
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-05-17
Tx date 2017-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-717 vol
51,163
Filed 2017-05-17
Tx date 2017-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-2,081.04
-232 vol
$8.97 each
1,445
Filed 2017-05-17
Tx date 2017-05-15
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$3,230
+361 vol
$8.95 each
242,433
Filed 2017-05-17
Tx date 2017-05-15
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+717 vol
1,677
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+547 vol
547
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-6,632 vol
184,924
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+6,632 vol
6,632
Filed 2017-05-11
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-2,393 vol
86,546
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-6,688.20
-710 vol
$9.42 each
1,683
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-547 vol
21,653
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,526.04
-162 vol
$9.42 each
385
Filed 2017-05-11
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-375 vol
51,880
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-349 vol
52,255
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,139.82
-121 vol
$9.42 each
960
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+375 vol
1,081
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+349 vol
819
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-274 vol
48,526
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-876.06
-93 vol
$9.42 each
181
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-21,176.16
-2,248 vol
$9.42 each
4,384
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+274 vol
274
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-1,064.46
-113 vol
$9.42 each
706
Filed 2017-05-11
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-05-11
Tx date 2017-05-09
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+2,393 vol
2,393
Filed 2017-05-11
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2017-05-03
Tx date 2017-05-01
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+20,000 vol
46,665
Filed 2017-04-06
Tx date 2017-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
11 - Acquisition or disposition carried out privately
$-612.18
-57 vol
$10.74 each
470
Filed 2017-04-06
Tx date 2017-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-178 vol
52,604
Filed 2017-04-06
Tx date 2017-04-01
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+178 vol
527
Filed 2017-04-05
Tx date 2017-03-30
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-04-05
Tx date 2017-03-30
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
9,600
Filed 2017-04-05
Tx date 2017-03-30
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
Filed 2017-04-05
Tx date 2017-03-30
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-04-05
Tx date 2017-03-30
$NVLN
Novelion Therapeutics Inc.
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
Filed 2017-02-03
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-456 vol
Filed 2017-02-03
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,388.24
-148 vol
$9.38 each
Filed 2017-02-03
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,388.24
-148 vol
$9.38 each
Filed 2017-02-03
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-456 vol
Filed 2017-01-31
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
36 - Conversion or exchange

-456 vol
1,367
Filed 2017-01-31
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
36 - Conversion or exchange

+456 vol
1,048
Filed 2017-01-31
Tx date 2017-01-27
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
10 - Acquisition or disposition in the public market
$-1,388.24
-148 vol
$9.38 each
900
Filed 2017-01-18
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
50 - Grant of options
$83,040
+9,600 vol
$8.65 each
Filed 2017-01-18
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
50 - Grant of options
$83,040
+9,600 vol
$8.65 each
Filed 2017-01-18
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-18
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-18
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-18
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
50 - Grant of options
$83,040
+9,600 vol
$8.65 each
Filed 2017-01-17
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$8.65
+1 vol
$8.65 each
1
Filed 2017-01-17
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$-8.65
-1 vol
$8.65 each
0
Filed 2017-01-17
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$8.65
+1 vol
$8.65 each
1
Filed 2017-01-17
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
$8.65
+1 vol
$8.65 each
1
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2017-01-13
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
8,110,740
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Common Shares
37 - Stock split or consolidation

-7,794,216 vol
1,948,554
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
8,110,740
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
8,110,740
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
2,840,909
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Warrants Fully Paid Warrant
37 - Stock split or consolidation

-2,272,728 vol
568,181
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-7,794,216 vol
1,948,554
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
8,110,740
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-29
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
2,840,909
Filed 2016-12-29
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Warrants Fully Paid Warrant
37 - Stock split or consolidation

-2,272,728 vol
568,181
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
VanLent, Anne
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
VanLent, Anne
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-3,282 vol
820
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-29,600 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
VanLent, Anne
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
9,600
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-29,600 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Rights Phantom Stock Units
37 - Stock split or consolidation

-22,720 vol
5,680
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
19,600
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-57,200
-40,000 vol
$1.43 each
10,000
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+171,660 vol
191,556
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-79,587 vol
19,896
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+323,520 vol
323,520
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Stern, Donald
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
9,600
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Stern, Donald
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-7,292 vol
1,823
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
9,600
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-2,371 vol
592
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-29,600 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-29,600 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Rights Phantom Stock Units
37 - Stock split or consolidation

-22,720 vol
5,680
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
19,600
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-57,200
-40,000 vol
$1.43 each
10,000
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-29,600 vol
7,400
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Plutzky, Jorge
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
9,600
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Plutzky, Jorge
4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+81,760 vol
88,939
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-28,717 vol
7,179
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+166,020 vol
166,020
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+81,760 vol
81,760
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+166,020 vol
166,020
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+47,980 vol
47,980
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+97,400 vol
97,400
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+20,560 vol
22,200
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-6,564 vol
1,640
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+41,740 vol
41,740
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Fully Paid Warrant
37 - Stock split or consolidation

-2,272,728 vol
568,181
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-6,488,592 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-6,488,592 vol
1,622,148
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-6,488,592 vol
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options
$83,040
+9,600 vol
$8.65 each
9,600
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-7,794,216 vol
1,948,554
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+47,980 vol
52,782
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-19,210 vol
4,802
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+97,400 vol
97,400
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-1,398 vol
349
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-62,800 vol
15,700
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-62,800 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-62,800 vol
15,700
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-62,800 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Rights Phantom Stock Units
37 - Stock split or consolidation

-22,720 vol
5,680
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
87,600
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-72,000
-40,000 vol
$1.80 each
78,000
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-286,000
-200,000 vol
$1.43 each
118,000
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-321,840
-72,000 vol
$4.47 each
318,000
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+47,980 vol
48,800
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Options
50 - Grant of options

+97,400 vol
97,400
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
50 - Grant of options
$83,040
+9,600 vol
$8.65 each
9,600
Filed 2016-12-27
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-369,183 vol
92,295
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-369,183 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-968,291 vol
242,072
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation

-968,291 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-369,183 vol
92,295
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-369,183 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-968,291 vol
242,072
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation

-968,291 vol
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Rights Phantom Stock Units
37 - Stock split or consolidation

-45,440 vol
11,360
Filed 2016-12-27
Tx date 2016-12-22
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+9,600 vol
29,600
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Options
37 - Stock split or consolidation
$-114,400
-80,000 vol
$1.43 each
20,000
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-25,024 vol
6,256
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-66,212 vol
16,553
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Common Shares
37 - Stock split or consolidation

-509,966 vol
127,491
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-968,291 vol
242,072
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
37 - Stock split or consolidation

-3,282 vol
820
Filed 2016-12-27
Tx date 2016-12-16
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Common Shares
37 - Stock split or consolidation

-62,800 vol
15,700
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+37,000 vol
37,000
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+37,000 vol
37,000
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+99,483 vol
99,483
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+9,115 vol
9,115
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+2,963 vol
2,963
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Smith, Sandford
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+37,000 vol
37,000
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+37,000 vol
37,000
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+35,896 vol
35,896
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+8,204 vol
8,204
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Fully Paid Warrant
16 - Acquisition or disposition under a prospectus exemption

+2,840,909 vol
2,840,909
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
16 - Acquisition or disposition under a prospectus exemption

+2,840,909 vol
8,110,740
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+5,269,831 vol
5,269,831
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
16 - Acquisition or disposition under a prospectus exemption

+2,840,909 vol
8,110,740
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+5,269,831 vol
5,269,831
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+4,472,939 vol
9,742,770
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
5,269,831
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+7,486 vol
24,012
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+5,230 vol
16,526
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+2,564 vol
11,296
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+1,777 vol
8,732
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+3,589 vol
6,955
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+3,366 vol
3,366
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+1,747 vol
1,747
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+78,500 vol
78,500
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+78,500 vol
78,500
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-12-06
$NVLN
Novelion Therapeutics Inc.
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
Options
50 - Grant of options

+50,000 vol
390,000
Filed 2016-12-09
Tx date 2016-12-06
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
56 - Grant of rights

+75,000 vol
75,000
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+26,665 vol
26,665
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Options
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+4,102 vol
4,102
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
9,742,770
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
Common Shares
00 - Opening Balance-Initial SEDI Report
9,742,770
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+461,478 vol
461,478
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
16 - Acquisition or disposition under a prospectus exemption

+1,136,363 vol
1,210,363
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend

+74,000 vol
74,000
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+461,478 vol
461,478
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
16 - Acquisition or disposition under a prospectus exemption

+1,136,363 vol
1,210,363
Filed 2016-12-09
Tx date 2016-11-23
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
35 - Stock dividend

+74,000 vol
74,000
Filed 2016-12-09
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-09
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-08
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
VanLent, Anne
4 - Director of Issuer
Direct Ownership
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+4,102 vol
4,102
Filed 2016-12-08
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
VanLent, Anne
4 - Director of Issuer
Direct Ownership
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-08
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-08
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-02
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+31,280 vol
31,280
Filed 2016-12-02
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-02
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+82,765 vol
82,765
Filed 2016-12-02
Tx date 2012-06-04
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
Common Shares
00 - Opening Balance-Initial SEDI Report
Filed 2016-12-02
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition

+175,979 vol
637,457
Filed 2016-12-02
Tx date 2016-11-29
$NVLN
Novelion Therapeutics Inc.
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
Common Shares
16 - Acquisition or disposition under a prospectus exemption
$1,999,998
+1,136,363 vol
$1.76 each
1,210,363